Advertisement
Advertisement
MRNA
Moderna, Inc. Common Stock
53.57
USDSponsored
+0.03
+0.05%
Mar 26, 15:45 UTC -4
Open
MRNA Earnings Reports
Positive Surprise Ratio
MRNA beat 20 of 29 last estimates.
69%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$232.19M
/-$2.12
Implied change from Q4 25 (Revenue/ EPS)
-65.75%
/+0.47%
Implied change from Q1 25 (Revenue/ EPS)
+114.99%
/-15.87%
Moderna, Inc. Common Stock earnings per share and revenue
On Feb 13, 2026, MRNA reported earnings of -2.11 USD per share (EPS) for Q4 25, beating the estimate of -2.69 USD, resulting in a 21.72% surprise. Revenue reached 678.00 million, compared to an expected 638.62 million, with a 6.17% difference. The market reacted with a +17.02% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 10 analysts forecast an EPS of -2.12 USD, with revenue projected to reach 232.19 million USD, implying an increase of 0.47% EPS, and decrease of -65.75% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Moderna, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Moderna, Inc. Common Stock reported EPS of -$2.11, beating estimates by 21.72%, and revenue of $678.00M, 6.17% above expectations.
How did the market react to Moderna, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 17.02%, changed from $33.84 before the earnings release to $39.60 the day after.
When is Moderna, Inc. Common Stock expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Moderna, Inc. Common Stock's next earnings report?
Based on 10
analysts, Moderna, Inc. Common Stock is expected to report EPS of -$2.12 and revenue of $232.19M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement